Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017339 | 1.00 | FAAH (0.40) | FAAHMEN1CYP1A2KMT2APAOX | |
| Tresperimus SCHEMBL9173994 | 0.92 | HDAC6 (0.43) | FAAHMEN1CYP1A2KMT2APAOX | |
| Trifluoroacetic Acid SCHEMBL9178492 | 0.92 | HDAC6 (0.43) | FAAHMEN1CYP1A2KMT2APAOX | |
| SCHEMBL13197478 | 0.86 | PAOX (0.38) | MEN1CYP1A2KMT2APAOXSMN1; SMN2 | |
| SCHEMBL525137 | 0.84 | PAOX (0.47) | MEN1CYP1A2KMT2APAOXSMN1; SMN2 | |
| SCHEMBL524786 | 0.84 | PAOX (0.47) | MEN1CYP1A2KMT2APAOXSMN1; SMN2 | |
| Anisperimus SCHEMBL8778912 | 0.83 | FAAH (0.39) | FAAHMEN1CYP1A2KMT2ASMN1; SMN2 | |
| Anisperimus SCHEMBL8778920 | 0.83 | FAAH (0.39) | FAAHMEN1CYP1A2KMT2ASMN1; SMN2 | |
| Anisperimus SCHEMBL8778901 | 0.83 | FAAH (0.39) | FAAHMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL8412131 | 0.83 | ACHE (0.40) | PAOXCA12CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2181704-A2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1594459-B1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INT AG (CH) | 2010-02-17 | — | — | EP | claimed |
| EP-0600762-B1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER IND & SANTE (FR) | 1996-07-10 | — | — | EP | claimed |
| US-5476870-A | Immunosuppressants | FOURNIER INDUSTRIE ET SANTE (FR) | 1995-12-19 | — | — | US | claimed |
| EP-0600762-A1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER INDUSTRIE ET SANTE (FR) | 1994-06-08 | — | — | EP | claimed |
| JP-6293728-A | — | — | None | — | — | JP | disclosed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132462-A1 | METHODS AND SYSTEMS FOR MONITORING A RECIPIENT OF AN ALLOGRAFT | CAREDX INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4314340-B1 | COMPOSITIONS AND METHODS FOR SIMULTANEOUS GENETIC ANALYSIS OF MULTIPLE LIBRARIES | RESOLUTION BIOSCIENCE INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20020142000-A1 | Anti-CD3 immunotoxins and therapeutic uses therefor | DIGAN MARY ELLEN (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001087982-A2 | IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1141023-A2 | ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES THEREFOR | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000041474-A2 | ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES THEREFOR | NOVARTIS AG (CH) | 2000-07-20 | — | — | WO | disclosed |
| EP-0600762-B1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER IND & SANTE (FR) | 1996-07-10 | — | — | EP | disclosed |
| JP-H06293728-A | 15-DEOXYSPERGUALIN ANALOG, ITS PREPARATION AND ITS USE IN THERAPY | FOURNIER IND & SANTE | 1994-10-21 | — | — | JP | disclosed |
| EP-0600762-A1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER INDUSTRIE ET SANTE (FR) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | FAAH 3049/4885MEN1 2648/4885CYP1A2 3960/4885 |
| US-20020142000-A1 | Anti-CD3 immunotoxins and therapeutic uses therefor | FCGRT, DNTT, CD40 | FAAH 2189/4885MEN1 4029/4885CYP1A2 4369/4885 |
| US-20260132462-A1 | METHODS AND SYSTEMS FOR MONITORING A RECIPIENT OF AN ALLOGRAFT | HLA-C, HLA-A, HLA-B | FAAH 3976/4885MEN1 3512/4885CYP1A2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.